Bispecific antibody · Immune activation, directed at CD123 (interleukin-3 receptor alpha chain) (IL3RA) and CD3 complex (CD3E) · developed by Xencor
Vibecotamab is a bispecific monoclonal antibody that binds CD123 on tumor cells and the CD3 complex on T cells, crosslinking cytotoxic T lymphocytes to CD123-expressing cells to trigger their lysis. It retains most of the native Fc domain, which prolongs half-life. It is studied in acute myelogenous leukemia, B-cell acute lymphoblastic leukemia, blastic plasmacytoid dendritic cell neoplasm, and chronic myeloid leukemia in blast crisis.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT02730312 | Phase 1 | Acute Myelogenous Leukemia | Completed | XNCR |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Acute Myelogenous LeukemiaB-cell Acute Lymphoblastic LeukemiaBlastic Plasmacytoid Dendritic Cell NeoplasmChronic Myeloid Leukemia, Blast Crisis
Updated Nov 1, 2026. Something wrong or missing? Report it on the XNCR page.
See XNCR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
XNCR catalysts and pipeline →